Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.40 |
| ▸ | RORC | P51449 | 9/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | CTSE | P14091 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9951201 | 0.89 | MGLL (0.38) | MGLLRORCGPR119 | |
| SCHEMBL9950570 | 0.89 | MGLL (0.38) | MGLLRORCKDM1AGPR119JAK1 | |
| SCHEMBL2733601 | 0.85 | MGLL (0.37) | MGLLRORCBACE1CTSDCTSE | |
| SCHEMBL9951537 | 0.80 | MAOA (0.41) | MGLLRORC | |
| SCHEMBL9951463 | 0.78 | MGLL (0.35) | MGLL | |
| SCHEMBL13201877 | 0.78 | GPR119 (0.44) | MGLLRORCNR1H2KDM1AGPR119 | |
| SCHEMBL8246876 | 0.78 | GPR119 (0.44) | MGLLRORCNR1H2KDM1AGPR119 | |
| SCHEMBL2366683 | 0.77 | KMT2A (0.50) | GPR119 | |
| SCHEMBL2366680 | 0.77 | KMT2A (0.50) | GPR119 | |
| SCHEMBL9951786 | 0.76 | GPR119 (0.49) | MGLLRORCGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906913-B2 | Azabicyclohexanes | PANACEA BIOTEC LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | MGLL 4807/4885RORC 113/4885NR1H2 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.